GlassScriptPhysician profile
Charles B Rives
NPI 1083057814
$6,042.30
in general payments reported to CMS, 2019-2025
33 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,087 · 2020: $175 · 2021: $693 · 2022: $499 · 2023: $801 · 2024: $1,423 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,574 · Education: $14.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,574.10 |
| Education | $14.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.03 | 2019-2025 | Viberzi, Linzess, Skyrizi |
| Boston Scientific Corporation | $783.82 | 2019-2025 | Axonics |
| Phathom Pharmaceuticals, INC. | $769.90 | 2024-2025 | Voquezna |
| Genzyme Corporation | $484.10 | 2023-2025 | |
| Celgene Corporation | $399.72 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $332.40 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $265.64 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Enterra Medical, INC. | $245.65 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.71 | 2019-2023 | Trulance |
| Lilly USA, LLC | $189.11 | 2024-2025 | Omvoh |
| Axonics, INC. | $157.57 | 2024 | Axonics |
| Pfizer INC. | $141.12 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $137.37 | 2019-2024 | Dificid |
| Shionogi INC | $132.59 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $120.15 | 2022-2024 | Rebyota |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $85.39 | 2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $76.57 | 2023-2024 | Dupixent |
| Medtronic, INC. | $61.21 | 2023-2024 | Gi Genius, Interstim |
| Janssen Biotech, INC. | $49.27 | 2021-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $47.17 | 2019-2025 | |
| Redhill Biopharma INC. | $40.70 | 2021 | |
| Astellas Pharma US INC | $40.08 | 2023-2024 | Vyloy |
| Amgen INC. | $37.36 | 2021-2025 | Uplizna |
| Ardelyx, INC. | $34.90 | 2024-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $32.10 | 2021-2023 | |
| Madrigal Pharmaceuticals | $30.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Alfasigma USA, INC. | $24.98 | 2021 | |
| Endogastric Solutions, INC | $20.87 | 2019 | |
| Daiichi Sankyo INC. | $19.01 | 2022 | |
| Qol Medical, LLC | $14.51 | 2021 | |
| Capsovision, INC. | $13.00 | 2023 | Capsocam Plus |
| Organon LLC | $12.68 | 2022 | |
| Ucb, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Rives listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.